CGH Future Directions
As cancer diseases and research continue to evolve, we too will move forward with stronger, more collaborative work. Looking ahead, the Center for Global Health has prioritized three key areas that shape our future directions, and work to acheive NCI’s goal of advancing global cancer research, building expertise, and leveraging resources across nations to address the challenges of cancer and reduce cancer deaths worldwide.
Increasing the Availability of Low-Cost, Portable Technologies
One of CGH's priorities is to increase the availability of low-cost, portable technologies for cancer diagnosis, imaging, and treatment in low- and middle-income countries (LMICs). As part of this effort, CGH works with other NCI divisions, offices, and centers to develop Cancer Detection, Diagnosis, and Treatment Technologies for Global Health, a funding opportunity to support teams of engineers, oncologists, and global health and business experts using the cooperative agreement mechanism to adapt existing technologies in areas such as minimally-invasive treatment and point-of-care imaging and in vitro technologies for diagnosis and detection. In addition to addressing unmet needs and the global cancer burden, technology development supported by this initiative has the potential to reduce cancer care costs in the United States. CGH will work to ensure that this initiative is integrated into other NIH-sponsored global health technology initiatives.
Training the Next Generation of Cancer Researchers
Training the next generation of cancer researchers and care providers, as well as tobacco control and cessation efforts, remain at the forefront of our work, as does developing palliative care initiatives. The work conducted by CGH staff in previous years in these areas has provided a solid foundation on which to build. Moving forward, CGH will pursue training, integration, and communication opportunities with scientists worldwide to improve cancer surveillance.
CGH continues to expand our partnerships and collaborations with foreign governments, nongovernmental organizations (NGOs), pharmaceutical and biotechnology companies, other NCI divisions, and U.S. government agencies. Specifically, we will engage the Centers for Disease Control and Prevention (CDC), NGOs, academic institutions, and NCI-designated cancer centers that have strong global health programs to develop a global cancer research strategy. In addition, CGH will work in consultation with the World Health Organization (WHO) and International Agency for Research on Cancer to coordinate global health programs for cancer control, as well as with pharmaceutical and biotechnology companies to develop new, inexpensive diagnostic tools to make novel cancer therapeutics available in a cost-effective manner to people in LMICs.